Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2

December 1, 2022 - 2 minutes
Photo/Shutterstock

Netherlands-based ISA Pharmaceuticals B.V., has announced that it has completed enrolment in its phase 2 clinical trial. Named OpcemISA. The trial aims to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive oropharyngeal cancer (OPC).

The clinical stage biotech company is developing immunotherapies to treat cancers and infectious diseases, and has enrolled 194 patients on its trial which is a large randomized, double blind, placebo-controlled phase 2 clinical trial. The trial will evaluate the efficacy and safety of the addition of ISA101b to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive OPC.

Extensive clinical development program

Primary endpoints will demonstrate overall response rate (ORR) and safety. Secondary endpoints include duration of response (DOR) and overall survival (OS). This trial is part of an extensive clinical development program of ISA101b in collaboration with US biotechnology company Regeneron.

Leon Hooftman, chief medical officer of ISA Pharmaceuticals, said: “This large proof of concept trial of ISA101b has the potential to demonstrate for the first time that the combination of an HPV16-directed therapeutic vaccine with checkpoint inhibitor immunotherapy improves the short-term outcome and longer-term survival of difficult to treat head and neck cancer patients.

HPV16 positive OPC a major cause of head and neck cancer

The completion of enrolment is a major milestone for ISA Pharmaceuticals as it continues development of its SLP technology platform. We look forward to presenting top line interim data from this trial in the third quarter of next year.”

Head-and-neck cancer can be a severe and life-threatening disease. HPV16 is a major cause of head-and-neck cancer. Recurrent and metastatic HPV16 positive OPC is a form of head-and-neck cancer with a high unmet medical need. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive oropharyngeal cancer (OPC).

Content continues below

Related Content

You might also be interested in the following: